NCT07872046: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors
- State
- Not started
- Phase
- Phase 3
- People
- 16,390 planned
- Started
- 30 Nov 2026
- Primary completion
- 25 Nov 2032
- Arms
- RZV Group
- Results
- None posted
- 13 Oct 2026: Trial registered